EP3856177A4 - Formes posologiques unitaires de grapiprant - Google Patents

Formes posologiques unitaires de grapiprant Download PDF

Info

Publication number
EP3856177A4
EP3856177A4 EP19865430.3A EP19865430A EP3856177A4 EP 3856177 A4 EP3856177 A4 EP 3856177A4 EP 19865430 A EP19865430 A EP 19865430A EP 3856177 A4 EP3856177 A4 EP 3856177A4
Authority
EP
European Patent Office
Prior art keywords
grapiprant
dosage forms
unit dosage
unit
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19865430.3A
Other languages
German (de)
English (en)
Other versions
EP3856177A1 (fr
Inventor
Mark Manfredi
Jeffrey Ecsedy
Atsushi Nagahisa
Takako Okumura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Askat Inc
Arrys Therapeutics Inc
Original Assignee
Askat Inc
Arrys Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Askat Inc, Arrys Therapeutics Inc filed Critical Askat Inc
Publication of EP3856177A1 publication Critical patent/EP3856177A1/fr
Publication of EP3856177A4 publication Critical patent/EP3856177A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP19865430.3A 2018-09-27 2019-09-27 Formes posologiques unitaires de grapiprant Pending EP3856177A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737285P 2018-09-27 2018-09-27
US201962834513P 2019-04-16 2019-04-16
PCT/US2019/053413 WO2020069288A1 (fr) 2018-09-27 2019-09-27 Formes posologiques unitaires de grapiprant

Publications (2)

Publication Number Publication Date
EP3856177A1 EP3856177A1 (fr) 2021-08-04
EP3856177A4 true EP3856177A4 (fr) 2022-06-29

Family

ID=69953354

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19865430.3A Pending EP3856177A4 (fr) 2018-09-27 2019-09-27 Formes posologiques unitaires de grapiprant

Country Status (6)

Country Link
US (1) US20210353648A1 (fr)
EP (1) EP3856177A4 (fr)
JP (1) JP2022500485A (fr)
CN (1) CN113260363A (fr)
CA (1) CA3113468A1 (fr)
WO (1) WO2020069288A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3781162A1 (fr) 2018-04-16 2021-02-24 Arrys Therapeutics, Inc. Inhibiteurs d'ep4 et leurs utilisations
WO2021205367A1 (fr) * 2020-04-08 2021-10-14 Askat Inc. Utilisation d'antagonistes du récepteur ep4 pour le traitement du cancer du foie, d'un mélanome, d'un lymphome et de la leucémie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422779A1 (fr) * 2009-04-22 2012-02-29 RaQualia Pharma Inc Substance agoniste sélective du récepteur ep4 pour le traitement du cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057267A2 (fr) * 2006-10-27 2008-05-15 Fmc Corporation Cellulose microcristalline et alcool de sucre co-traités servant d'excipient pour des formulations de comprimés
JP2014520865A (ja) * 2011-07-15 2014-08-25 ユーファーマ プロプライエタリー リミテッド 制酸剤、麻酔薬、ならびに二酸化ケイ素と二酸化チタンとを含んでなる無機マトリックスを含んでなる経口用組成物
ES2671998T3 (es) * 2013-07-16 2018-06-12 Cadila Pharmaceuticals Ltd. Derivados de indol-3-carbinol
PL3113774T3 (pl) * 2014-03-06 2022-06-13 Elanco Animal Health Incorporated Kompozycje grapiprantu i sposoby ich zastosowania

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422779A1 (fr) * 2009-04-22 2012-02-29 RaQualia Pharma Inc Substance agoniste sélective du récepteur ep4 pour le traitement du cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer - Full Text View - ClinicalTrials.gov", 5 September 2018 (2018-09-05), XP055922589, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT03658772> [retrieved on 20220518] *
KNYCH HEATHER K. ET AL: "Detection and pharmacokinetics of grapiprant following oral administration to exercised Thoroughbred horses", DRUG TESTING AND ANALYSIS, vol. 10, no. 8, 25 March 2018 (2018-03-25), GB, pages 1237 - 1243, XP055919467, ISSN: 1942-7603, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fdta.2378> DOI: 10.1002/dta.2378 *
MOUSUMI MAJUMDER ET AL: "EP4 as a Therapeutic Target for Aggressive Human Breast Cancer", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 19, no. 4, 1 January 2018 (2018-01-01), Basel, CH, pages 1019, XP055600668, ISSN: 1661-6596, DOI: 10.3390/ijms19041019 *
RAUSCH-DERRA L. C. ET AL: "Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs", JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS., vol. 39, no. 6, 1 December 2016 (2016-12-01), GB, pages 566 - 571, XP055919497, ISSN: 0140-7783, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/jvp.12306> DOI: 10.1111/jvp.12306 *
See also references of WO2020069288A1 *

Also Published As

Publication number Publication date
CA3113468A1 (fr) 2020-04-02
JP2022500485A (ja) 2022-01-04
US20210353648A1 (en) 2021-11-18
CN113260363A (zh) 2021-08-13
EP3856177A1 (fr) 2021-08-04
WO2020069288A1 (fr) 2020-04-02

Similar Documents

Publication Publication Date Title
EP3803740A4 (fr) Protection de chaîne de blocs
EP3801265A4 (fr) Débitmètre urinaire
EP3778036A4 (fr) Inhalateur
EP3768258A4 (fr) Polythérapie
EP3802562A4 (fr) Nouvelle utilisation pharmaceutique
EP3893874A4 (fr) Traitement combiné à base de crénolanib
EP3486371B8 (fr) Unité de commutation de rail
EP3804828A4 (fr) Unité de connexion
EP3784463A4 (fr) Fluorosulfones
EP3612522A4 (fr) Composés thérapeutiques
EP3721129A4 (fr) Cryosphère
EP3856177A4 (fr) Formes posologiques unitaires de grapiprant
EP3876716A4 (fr) Support cryogénique
EP3834079A4 (fr) Configuration à réponses multiples et à questions multiples
EP3697393A4 (fr) Formes posologiques pharmaceutiques
EP3773102A4 (fr) Distributeur
EP3738602A4 (fr) Cytocide
EP3826927B8 (fr) Distributeur
AU2019245399B2 (en) Dispenser
EP3675842A4 (fr) Formes posologiques pharmaceutiques
AU2018101027A4 (en) PadPay
EP3883561A4 (fr) Procédés pharmaceutiques
EP3830662A4 (fr) Dispositif de surveillance de plantes
EP3801506A4 (fr) Polythérapie
EP3797079A4 (fr) Revêtement cryogénique

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210316

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40059394

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031435300

Ipc: A61K0031640000

A4 Supplementary search report drawn up and despatched

Effective date: 20220527

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20220523BHEP

Ipc: A61P 35/00 20060101ALI20220523BHEP

Ipc: A61P 19/02 20060101ALI20220523BHEP

Ipc: A61K 9/20 20060101ALI20220523BHEP

Ipc: A61K 9/14 20060101ALI20220523BHEP

Ipc: A61K 9/00 20060101ALI20220523BHEP

Ipc: A61K 31/64 20060101AFI20220523BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230428

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240411